Market Highlights
The transthyretin amyloidosis market is expected to register
a sturdy growth during the forecast period.
Transthyretin amyloidosis is a genetical disorder that is characterized
by the buildup of abnormal deposits of a protein called amyloid (amyloidosis)
in a body's organs and tissues. They generally affect peripheral neuropathic or
autonomic neuropathy system and cardiac system. The cardiac form of
transthyretin amyloidosis puts patients at the risk of arrhythmia,
cardiomegaly, and orthostatic hypertension. The global ATTR market is going to
exhibit robust growth during the forecast period due to the probability of
rising number of the launch of ATTR therapeutic drugs, increasing
African-American population as they are genetically susceptible to the disease,
increasing healthcare awareness among people, and rising average income of
individuals. However, the growth of this market can be hindered by stringent
regulatory policies, the high cost of ATTR drugs, incorrect diagnosis of ATTR
disorders, and limitation of clinical trials.
Access Report @ https://www.marketresearchfuture.com/reports/transthyretin-amyloidosis-market-6155
Americas is a global leader in the market for transthyretin
amyloidosis owing to the increasing prevalence of amyloidosis among adults and
older population and rising geriatric population which is a major trigger
factor for this disease. For instance, according to a report published by ASCO
Journal in 2016 around 4,000 people develop amyloidosis each year in the United
States. Thus, this huge patient pool is going to boost up the market growth
during the forecast period. Additionally, factors such as increasing government
initiatives and funding for research, development in advanced medical treatment
options, rising use of advanced medical diagnostic devices, and availability of
skilled professionals drive the market. The presence of pharmaceutical giants such
as Pfizer, Merck, etc. also propels the market growth in this region. Pfizer
and Merck have a monopoly in this market due to tafamidis and diflunisal drug.
Europe holds a healthy share in the global transthyretin
amyloidosis market and is a second market leader. The European market is
expected to grow during the forecast period due to major driving factors such
as huge patient pool, availability of advanced treatment facilities, increasing
healthcare expenditure, along with growing need for better healthcare
infrastructure, and government initiatives of healthcare reform. It is reported that in the U.K., around 60
new cases of amyloidosis are reported annually, and the age-specific incidence
rate of it is between 5.1 and 12.8 per million per year. Additionally,
established medical device market and capability of inhabitants to afford the
diagnostics are aiding the market growth. However, the inefficacy of treatment
and wrong diagnosis are hampering the market growth of this region.
Asia Pacific is expected to be the fastest growing market
due to increasing geriatric population. On the basis of a report that was
published by the United Nations in 2015; between 2015 and 2030, the number of
older people aged 60 years or over in the world is predicted to grow by 56 %,
out of which 66% of the older population would reside in Asia-Pacific regions.
This makes the region prone to transthyretin amyloidosis as chances of its
prevalence increases with increasing age. Owing to the huge patient pool, a
faster adaptation of healthcare technology, government initiatives to increase
the healthcare quality, availability favorable insurance and reimbursement
policies market growth will be accelerated during the forecast period. Moreover, key players such as Pfizer, Merck, etc.
have been setting up their regional headquarters and manufacturing plants in
Singapore, China, Japan, Korea, and Australia. This will accelerate the market
growth during the forecast period.
The Middle East &
Africa is expected to show the least growth in the market due to some major
factors such as lack of awareness, limited access and availability of treatment
facilities. In the Middle East, the growth of the market is driven by Saudi
Arabia and the United Arab Emirates because of the well-established healthcare
infrastructure, awareness for good health among the residents, as well as
accessibility to modern medical technology methods. But market might show
steady growth due to genetically susceptibility of Africans to transthyretin
amyloidosis and government initiatives to improve quality of healthcare in this
region.
Segmentation
The global Transthyretin (TTR) amyloidosis market is
segmented on the basis of disease type, treatment, gender, and end-user.
Considering the type of disease, the market is segmented
into Transthyretin (TTR) familial amyloid polyneuropathy, Transthyretin (TTR)
familial amyloid cardiomyopathy and others.
On the basis of treatment, the market is segmented into
small molecules treatment, RNAi therapy, and Organ Transplantation and others.
Small molecules treatment is further segmented into tafamidis and diflunisal.
On gender basis it is segmented into male and female.
According to end-user, the market is segmented hospitals
& clinics, ambulatory surgical centers, and others.
Based on region the market is segmented into Americas,
Europe, Asia Pacific, and the Middle East and Africa. Americas region is
segmented into North America and South America. Similarly, Europe is segmented
into Western Europe and Eastern Europe.
Key Players
Some of the key players in the Transthyretin amyloidosis
market are Alnylam Pharmaceuticals, Pfizer, Ionis Pharmaceuticals Inc., Corino
Therapeutics Inc, Arcturus Therapeutics, and Proclara Bioscience.
About Market Research Future:
At Market Research Future
(MRFR), we enable our customers to unravel the complexity of various industries
through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR),
Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research
& Consulting Services.
MRFR team have supreme
objective to provide the optimum quality market research and intelligence
services to our clients. Our market research studies by Components,
Application, Logistics and market players for global, regional, and country
level market segments, enable our clients to see more, know more, and do more,
which help to answer all their most important questions.
In order to stay updated with
technology and work process of the industry, MRFR often plans & conducts
meet with the industry experts and industrial visits for its research analyst
members.
Contact:
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune – 411028
Maharashtra, India
+1 646 845 9312
Email: sales@marketresearchfuture.com
Blog: https://healthcarenews12.blogspot.com/
